Infusion Reactions Are the Main Side Effect of Monoclonal Antibody Medications
Infusion reactions (IRs) represent the most common adverse effect of monoclonal antibody medications, occurring across virtually all monoclonal antibodies with widely varying incidence rates. 1
Understanding Infusion Reactions
Infusion reactions are acute adverse events that occur during or shortly after monoclonal antibody administration. The mechanisms underlying these reactions include:
- Cytokine release syndrome (CRS) - particularly with antibodies targeting lymphocytes
- Non-specific immune activation
- True hypersensitivity reactions (less common)
The incidence varies dramatically by specific agent, ranging from <1% with checkpoint inhibitors to 77% with rituximab on first infusion 1.
Incidence by Specific Agents
The ESMO Clinical Practice Guidelines 1 provide detailed incidence data:
High incidence agents:
- Rituximab: 77% on first infusion (decreases with subsequent doses); severe reactions in 10% of patients 1
- Blinatumomab: 44-67% overall; serious reactions only 0.5% 1
Moderate incidence agents:
- Brentuximab vedotin: 11-15%, mostly grade 1/2 1
Low incidence agents:
- Bevacizumab: <3% during first infusion; severe <1% 1
- Trastuzumab: Most IRs mild, occur on first infusion; severe reactions rare 1
- Checkpoint inhibitors (PD-1/PD-L1): <1% in phase III studies 1
- Atezolizumab: 1-2% 1
- Alemtuzumab: Serious reactions in 3% 1
Clinical Presentation
Common symptoms include 1:
- Constitutional: Fever, chills, rigors, fatigue
- Dermatologic: Rash, flushing, pruritus, urticaria
- Respiratory: Dyspnea, chest discomfort
- Cardiovascular: Hypotension, tachycardia, blood pressure changes
- Gastrointestinal: Nausea, vomiting
- Neurologic: Headache, dizziness
Critical Risk Factors
Highest risk occurs during the first infusion - this is when 80% of severe rituximab reactions occur 1. Risk decreases substantially with subsequent administrations for most agents.
For rituximab specifically, patients with high circulating lymphocyte counts (>25 × 10⁹/L) or high tumor burden face elevated risk of severe cytokine release syndrome 1.
Prevention Strategies
The evidence-based approach varies by agent 1:
Mandatory premedication:
- Rituximab: Antipyretic + antihistamine always required [Level IV, Grade A] 1
- Alemtuzumab: Corticosteroids (methylprednisolone 1g) for first 3 days 1
- Blinatumomab: Dexamethasone 20mg IV 1 hour before infusion + antipyretic for first 48 hours of each cycle 1
No premedication recommended:
Infusion rate modifications:
- Slow initial infusion rates reduce risk across all agents 1
- Rituximab in high-risk patients: Consider split dosing over 2 days for first cycle 1
Management Algorithm
Grade 1-2 reactions 1:
- Stop or slow infusion rate
- Symptomatic treatment
- Resume at slower rate after symptom resolution
Grade 3-4 reactions 1:
- Immediately stop infusion
- Aggressive symptomatic treatment
- For most agents: Can resume at slower rate after complete resolution (unless severe anaphylaxis)
- For atezolizumab: Permanently discontinue 1
Important Clinical Caveats
The first infusion carries disproportionate risk - maintain heightened vigilance and slower infusion rates during initial administration. Most agents show dramatically reduced IR rates with subsequent doses 1.
Hypersensitivity reactions were more frequent than expected in real-world Korean surveillance data, occurring in almost 19% of patients 2. This suggests clinical practice may see higher rates than controlled trials.
Immunogenicity (formation of human anti-drug antibodies) occurs with almost all monoclonal antibodies but only causes clinically significant adverse consequences with select agents 3.
While infectious complications represent another common adverse effect class occurring across multiple monoclonal antibodies 3, 4, these typically manifest over longer timeframes rather than as acute reactions during administration. Infusion reactions remain the most immediate and universally relevant safety concern requiring active monitoring during every monoclonal antibody infusion.